MBRX - WPD pharmaceuticals to get $6.7M grant for development of Leukemia treatment

WPD Pharmaceuticals (WPDPF) announces that it has been conditionally awarded a grant of $6.7M from the Polish National Center for Research and Development (“NCRD”), for the development of annamycin, the company’s drug candidate used in the treatment of Acute Myeloid Leukemia (“AML”).The funds will be used on the continued development of Annamycin in combination treatment and is budgeted to cover about 60% of the planned costs of a Phase 1/2 combination drug clinical trial.WPD sublicenses the rights for Annamycin in 29 European and Asian countries from Moleculin Biotech (MBRX).

For further details see:

WPD pharmaceuticals to get $6.7M grant for development of Leukemia treatment